Silence Therapeutics plc (SLN)Healthcare | Biotechnology | London, United Kingdom | NasdaqGM
9.00 USD
-0.65
(-6.788%) ⇩
(Oct. 13, 2026, 2:32 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:33 a.m. EDT
Silence Therapeutics presents a classic biotech value trap with no safety net. The company is burning through cash at an alarming rate, generating negative operating cash flow and reporting massive losses, while holding virtually no debt but also no meaningful revenue to speak of. The balance sheet looks pristine on paper due to low leverage, but the liquidity runway is dangerously short given the cash burn. Fundamentally, this is a speculative gamble on a future cure rather than a viable business today. The market has already priced in this reality, evidenced by the crushing valuation multiples and the lack of analyst consensus beyond a generic 'buy' based on potential, not performance. While the stock recently found some support above the 200-day moving average, the technical structure remains fragile against the backdrop of deteriorating fundamentals. Options activity confirms the pessimism, with traders stacking protective puts at strikes significantly below the current price, betting on further declines or a failed clinical trial. There is no dividend to provide income, and the long-term outlook is precarious until the company can demonstrate a path to profitability or a major milestone that justifies the current premium. This is a high-risk speculative vehicle unsuitable for investors seeking stability or capital preservation. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.100102 |
| MSTL | 0.130108 |
| AutoTheta | 0.155153 |
| AutoETS | 0.155316 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.469 |
| Excess Kurtosis | -0.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.291 |
| Revenue per Share | 0.013 |
| Market Cap | 559,076,032 |
| Forward P/E | -23.67 |
| Beta | 1.45 |
| Website | https://www.silence-therapeutics.com |
As of Oct. 10, 2026, 1:33 a.m. EDT: Speculators are positioning heavily for downside protection, with significant open interest concentrated in out-of-the-money puts (strikes $5-$12.50) expiring late in 2026 and early 2027. Call activity is sparse and skewed toward deep out-of-the-money strikes ($15-$20), suggesting limited conviction in an immediate rally. Implied volatility is elevated on the put side relative to calls, indicating a market pricing in a higher probability of a drop than a surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6523973 |
| Address1 | 12 Hammersmith Grove |
| All Time High | 35.0 |
| All Time Low | 1.97 |
| Ask | 14.22 |
| Ask Size | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,117,710 |
| Average Daily Volume3 Month | 1,147,482 |
| Average Volume | 1,147,482 |
| Average Volume10Days | 1,117,710 |
| Beta | 1.445 |
| Bid | 7.92 |
| Bid Size | 2 |
| Book Value | 0.814 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.995 |
| Current Ratio | 7.416 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 9.565 |
| Day Low | 8.71 |
| Debt To Equity | 0.291 |
| Display Name | Silence Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,740,661,200 |
| Earnings Call Timestamp Start | 1,740,661,200 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -63,942,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.005 |
| Enterprise To Revenue | 624.371 |
| Enterprise Value | 383,988,448 |
| Eps Current Year | -0.365 |
| Eps Forward | -0.38 |
| Eps Trailing Twelve Months | -1.29 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.4904 |
| Fifty Day Average Change | -3.4954004 |
| Fifty Day Average Change Percent | -0.27984694 |
| Fifty Two Week Change Percent | 65.23973 |
| Fifty Two Week High | 17.576 |
| Fifty Two Week High Change | -8.581 |
| Fifty Two Week High Change Percent | -0.4882226 |
| Fifty Two Week Low | 4.19 |
| Fifty Two Week Low Change | 4.805 |
| Fifty Two Week Low Change Percent | 1.146778 |
| Fifty Two Week Range | 4.19 - 17.576 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,599,571,800,000 |
| Float Shares | 37,854,512 |
| Forward Eps | -0.38 |
| Forward P E | -23.671053 |
| Free Cashflow | -23,567,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 88 |
| Fullday Change | -0.65499973 |
| Fullday Change Percent | -6.787562 |
| Fullday Price | 8.995 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.85853994 |
| Gross Profits | 528,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07967 |
| Held Percent Institutions | 0.44606 |
| Implied Shares Outstanding | 62,154,086 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom. |
| Long Name | Silence Therapeutics plc |
| Market | us_market |
| Market Cap | 559,076,032 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_183280 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -59,953,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 745,849,032 |
| Number Of Analyst Opinions | 6 |
| Open | 9.53 |
| Operating Cashflow | -42,263,000 |
| Operating Margins | -104.7561 |
| Payout Ratio | 0.0 |
| Phone | 44 20 3457 6900 |
| Previous Close | 9.65 |
| Price Eps Current Year | -24.643835 |
| Price Hint | 2 |
| Price To Book | 11.050368 |
| Price To Sales Trailing12 Months | 909.0667 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.398 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.71429 |
| Region | US |
| Regular Market Change | -0.65499973 |
| Regular Market Change Percent | -6.787562 |
| Regular Market Day High | 9.565 |
| Regular Market Day Low | 8.71 |
| Regular Market Day Range | 8.71 - 9.565 |
| Regular Market Open | 9.53 |
| Regular Market Previous Close | 9.65 |
| Regular Market Price | 8.995 |
| Regular Market Time | 1,791,916,344 |
| Regular Market Volume | 807,836 |
| Return On Assets | -0.29646 |
| Return On Equity | -0.90409 |
| Revenue Per Share | 0.013 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,154,086 |
| Shares Percent Shares Out | 0.040799998 |
| Shares Short | 2,538,328 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,435,831 |
| Short Name | Silence Therapeutics Plc - Amer |
| Short Percent Of Float | 0.0502 |
| Short Ratio | 3.0 |
| Source Interval | 15 |
| Symbol | SLN |
| Target High Price | 75.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 33.0 |
| Target Median Price | 29.5 |
| Total Cash | 72,054,000 |
| Total Cash Per Share | 1.525 |
| Total Debt | 112,000 |
| Total Revenue | 615,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.308775 |
| Two Hundred Day Average Change | 0.68622494 |
| Two Hundred Day Average Change Percent | 0.082590386 |
| Type Disp | Equity |
| Volume | 807,836 |
| Website | https://www.silence-therapeutics.com |
| Zip | W6 7AP |